Autonomix Medical expands its patent portfolio, reports promising preclinical results for nerve ablation in pancreatic cancer treatment.
Quiver AI Summary
Autonomix Medical, Inc. has announced the issuance of a new U.S. patent (12,064,256) for its innovative cancer treatment technologies, expanding its global patent portfolio to over 120, which includes 80 issued patents and over 40 pending applications. The company focuses on addressing cancers involving the nervous system, initially targeting pancreatic cancer-related pain. Recent preclinical studies demonstrated significant reductions in tumor mass and metastases through a method called targeted nerve ablation. Autonomix is advancing its first-in-class catheter-based sensing platform capable of detecting neural signals with high sensitivity, combined with proprietary radio frequency ablation technology to treat various conditions, including chronic pain and hypertension. The company is currently conducting human clinical trials to evaluate pain reduction in pancreatic cancer patients and plans to further investigate the technology's potential to slow cancer progression.
Potential Positives
- Expansion of global patent portfolio to over 120 patents enhances protection and potential commercial value of the company's innovative technology.
- Statistically significant results from preclinical studies indicate potential effectiveness of the targeted nerve ablation technology in reducing tumor mass and cancer metastases, supporting further research and development.
- Introduction of first-in-class catheter-based microchip sensing technology offers enhanced sensitivity in detecting neural signals, potentially revolutionizing treatment strategies for chronic pain and other conditions.
- Focus on addressing pancreatic cancer pain, a significant unmet medical need, positions the company strategically within a critical area of healthcare innovation.
Potential Negatives
- Technology described in the press release is still investigational and has not yet been cleared for marketing in the United States, which may delay potential revenue and impact investor confidence.
- Forward-looking statements regarding the potential of their technology come with significant risks and uncertainties, suggesting that anticipated results may not materialize.
- The reliance on a preclinical mouse study to support claims about efficacy in humans raises questions about the robustness of the findings and their relevance to human clinical trials.
FAQ
What recent advancements has Autonomix Medical made in its patent portfolio?
Autonomix Medical has grown its global patent portfolio to over 120 patents, including 80 issued patents and over 40 pending applications.
What technology is covered by the newly issued '256 patent?
The '256 patent covers systems and methods for treating cancerous tumors and cancer-related pain, initially focusing on pancreatic cancer pain.
What were the results of the preclinical study conducted by Autonomix?
The preclinical study showed a statistically significant reduction in metastases and tumor mass through targeted nerve ablation techniques.
How does Autonomix's technology compare to current pain management methods?
The technology offers up to 3,000 times greater sensitivity in detecting neural signals compared to existing opioid or invasive treatments for chronic pain.
What are the potential applications of Autonomix's technology?
Autonomix's technology may address multiple indications beyond pain management, including cardiology and hypertension, using its catheter-based microchip sensing system.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$AMIX Hedge Fund Activity
We have seen 8 institutional investors add shares of $AMIX stock to their portfolio, and 12 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- TWO SIGMA SECURITIES, LLC added 23,673 shares (+inf%) to their portfolio in Q3 2024
- RENAISSANCE TECHNOLOGIES LLC removed 16,690 shares (-100.0%) from their portfolio in Q3 2024
- VIRTU FINANCIAL LLC removed 16,519 shares (-95.6%) from their portfolio in Q3 2024
- GEODE CAPITAL MANAGEMENT, LLC removed 16,202 shares (-78.3%) from their portfolio in Q3 2024
- UBS GROUP AG added 13,455 shares (+1749.7%) to their portfolio in Q3 2024
- TOWER RESEARCH CAPITAL LLC (TRC) removed 7,749 shares (-96.9%) from their portfolio in Q3 2024
- MARINER, LLC added 5,619 shares (+inf%) to their portfolio in Q3 2024
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
Growing global patent portfolio to over 120 patents with 80 issued patents and over 40 pending patent applications
Previously completed preclinical study evaluating targeted nerve ablation demonstrated statistically significant reduction of metastases and statistically significant reduction in tumor mass
THE WOODLANDS, TX, Dec. 30, 2024 (GLOBE NEWSWIRE) --
Autonomix Medical, Inc.
(NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced the United States Patent and Trademark Office (USPTO) has issued U.S. patent 12,064,256 (‘256 patent) titled,
Systems and Methods for Treating Cancer and/or Augmenting Organ Function
.
The issued ‘256 patent covers technology including, but not limited to, systems, methods and devices for interventionally treating cancerous tumors and cancer related pain. The Company is initially advancing the development of its technology to address pancreatic cancer-related pain.
“As we continue to advance the development of this potentially groundbreaking technology, bolstering our patent protection remains a key priority,” commented Brad Hauser, CEO of Autonomix. “Supported by recent positive preclinical results demonstrated to date, we believe the depth and breadth of our proprietary technology provides the opportunity for further evaluation and we intend to explore its potential to reduce cancer progression and metastases.”
Results from a
previously completed preclinical mouse study
evaluating the ability of targeted nerve ablation demonstrated statistically significant reduction of metastases and statistically significant reduction in tumor mass, further supporting that neural pathways are especially impactful in the pathogenesis of pancreatic cancer. While the Company’s ongoing proof-of-concept human clinical trial is strictly focused on pain reduction from the ablation of target nerves near the pancreas, additional studies will explore whether these preclinical findings translate to the clinical application of Autonomix’s technology. Based on the preclinical results demonstrated to date, the Company intends to further explore the potential of its ablation technology to slow human pancreatic cancer growth and metastasis.
Autonomix’s first-in-class catheter-based sensing technology is covered by its global patent portfolio with over 80 issued patents and over 40 pending patent applications. In addition to the ‘256 patent, the USPTO has recently issued 12,053,634 (‘634 patent) titled,
Endoscopic Sympathectomy Systems and Methods
, and 12,070,334 (‘334 patent) titled
, Elongated Conductors and Methods of Making and Using the Same
.
The Company’s first-in-class technology platform utilizes a catheter-based microchip sensing array antenna that has the ability to detect and differentiate neural signals with up to 3,000 times greater sensitivity than currently available technologies. Once target nerves are identified, Autonomix uses its proprietary radio frequency (RF) ablation technology to kill targeted nerves, enabling a precision guided sense, treat and verify approach to addressing a number of disease categories from chronic pain management to hypertension and cardiology. Current approaches, primarily relying on opioids or invasive ethanol injections, can provide only limited relief and may lead to risky side effects.
For more information about the Company’s technology, please visit
autonomix.com
.
About Autonomix Medical, Inc.
Autonomix is a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated. The Company’s first-in-class platform system technology includes a catheter-based microchip sensing array that may have the ability to detect and differentiate neural signals with approximately 3,000 times greater sensitivity than currently available technologies. We believe this will enable, for the first time ever, transvascular diagnosis and treatment of diseases involving the peripheral nervous system virtually anywhere in the body.
We are initially developing this technology for the treatment of pain, with initial trials focused on pancreatic cancer, a condition that causes debilitating pain and is without a reliable solution. Our technology constitutes a platform to address dozens of potential indications, including cardiology, hypertension and chronic pain management, across a wide disease spectrum. Our technology is investigational and has not yet been cleared for marketing in the United States.
For more information, visit
autonomix.com
and connect with the Company on
X
,
LinkedIn
,
Instagram
and
Facebook
.
Forward Looking Statements
Some of the statements in this release are “forward-looking statements,” which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, the potential of the technology to treat cancerous tumors and the pain associated with pancreatic cancer. Such forward-looking statements can be identified by the use of words such as “should,” “might,” “may,” “intends,” “anticipates,” “believes,” “estimates,” “projects,” “forecasts,” “expects,” “plans,” and “proposes.”
Although Autonomix believes that the expectations reflected in these forward-looking statements are based on reasonable assumptions, there are a number of risks and uncertainties that could cause actual results to differ materially from such forward-looking statements. You are urged to carefully review and consider any cautionary statements and other disclosures, including the statements made under the heading “Risk Factors” and elsewhere in the Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) on May 31, 2024. Forward-looking statements speak only as of the date of the document in which they are contained and Autonomix does not undertake any duty to update any forward-looking statements except as may be required by law.
Investor and Media Contact
JTC Team, LLC
Jenene Thomas
908.824.0775
autonomix@jtcir.com
This article was originally published on Quiver News, read the full story.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
